Intravitreous vascular endothelial growth factor (VEGF) inhibitor therapy for tamoxifen induced macular edema

Dan H Bourla; Christine R Gonzales; Charles W Mango; Joel N Moral; Robert S Wirthlin; Steven D Schwartz

doi:10.1080/08820530701418524

Intravitreous vascular endothelial growth factor (VEGF) inhibitor therapy for tamoxifen induced macular edema

Semin Ophthalmol. 2007 Apr-Jun;22(2):87-8. doi: 10.1080/08820530701418524.

Authors

Dan H Bourla¹, Christine R Gonzales, Charles W Mango, Joel N Moral, Robert S Wirthlin, Steven D Schwartz

Affiliation

¹ Jules Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, CA 90095, USA. bourla@jsei.ucla.edu

PMID: 17564928
DOI: 10.1080/08820530701418524

Abstract

A 59-year-old male patient with tamoxifen induced macular edema in both eyes was treated with intravitreous sodium pegaptanib. Follow-up clinical examination, OCT, and FA demonstrated reduced edema and leakage with improvement in visual acuity.

Publication types

Case Reports

MeSH terms

Antineoplastic Agents, Hormonal / adverse effects*
Antineoplastic Agents, Hormonal / therapeutic use
Aptamers, Nucleotide / administration & dosage*
Aptamers, Nucleotide / therapeutic use
Astrocytoma / drug therapy
Brain Neoplasms / drug therapy
Humans
Injections
Macular Edema / chemically induced*
Macular Edema / drug therapy*
Macular Edema / physiopathology
Male
Middle Aged
Tamoxifen / adverse effects*
Tamoxifen / therapeutic use
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Visual Acuity / drug effects
Vitreous Body

Substances

Antineoplastic Agents, Hormonal
Aptamers, Nucleotide
Vascular Endothelial Growth Factor A
Tamoxifen
pegaptanib